Testing Immunotherapy Treatments for Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)
Treatment
Treatment study for people with endometrial cancer that has returned
Study Contact Information:
For additional information, please contact: the Principal Investigator: Haider S Mahdi at NRG Oncology 412-641-5609 or [email protected]
About the Study
This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.
What the Study Involves
This study involves 2 groups:
- Group 1:
Patients will receive both nivolumab and ipilimumab injected into the vein on day 1 of every other cycle. Cycles will repeat every three weeks and will be repeated for up to eight cycles. - Group 2:
Patients will receive nivolumab injected into the vein on day 1 of each cycle. This will repeat every three weeks for every eight weeks.
Study Sites
Georgia
Augusta
Augusta University Medical Center
Contact: Site Public Contact 706-721-2388 [email protected]
Iowa
Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Contact: Site Public Contact 800-237-1225
Missouri
Saint Louis
Washington University School of Medicine
Contact: Site Public Contact 800-600-3606 [email protected]
New Mexico
Albuquerque
University of New Mexico Cancer Center
Contact: Site Public Contact 505-925-0348 [email protected]
Ohio
Cleveland
Case Western Reserve University
Contact: Site Public Contact 800-641-2422 [email protected]
Cleveland
Cleveland Clinic Foundation
Contact: Site Public Contact 866-223-8100 [email protected]
Oklahoma
Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Site Public Contact 405-271-8777 [email protected]
Pennsylvania
Philadelphia
NRG Oncology
Contact: Haider S. Mahdi 412-641-5609 [email protected]
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Contact: Site Public Contact 412-647-8073
Rhode Island
Providence
Women and Infants Hospital
Contact: Site Public Contact 401-274-1122
Virginia
Charlottesville
University of Virginia Cancer Center
Contact: Site Public Contact 434-243-6303 [email protected]
Washington
Seattle
Fred Hutchinson Cancer Research Center
Contact: Site Public Contact 800-804-8824
This Study is Open To:
People 18 years or older who:
- have detectable recurrent endometrial cancer with dMMR (deficient mismatch repair)
- have received 1-2 prior lines of treatment, but must have been stopped at least 4 weeks prior to the start of the trial
- have recovered from the effects of any recent surgeries or cancer treatments
- agree to use contraceptives prior to the study and five months following following the study, as well as test negative for pregnancy or not be breastfeeding
- do not have detectable HBV, HIV or HCV
This Study is Not Open To:
People who:
- have a diagnosis of endometrial serous cancer
- are receiving immunosuppressive therapy
- have an active autoimmune disease or weak immune systems that may be unable to respond to the treatment
- are pregnant or unwilling to stop nursing
- have had prior therapy with a treatment similar to the therapy being used in the trial
- have had a history of allergic reactions to materials similar to the treatment being given in the study
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.